Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

NCT00086125 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies
Leukemia
Myelodysplastic Syndromes
Myeloid Metaplasia
Lymphoma

Interventions

DRUG: ridaforolimus

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]